Targeting c‐Met in Cancer by MicroRNAs: Potential Therapeutic Applications in Hepatocellular Carcinoma

Preclinical Research

[1]  Y. Liu,et al.  MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. , 2015, Molecular medicine reports.

[2]  C. Peng,et al.  The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy , 2015, Cancer investigation.

[3]  Guangfeng Niu,et al.  miR‐454 is down‐regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c‐Met , 2015, Cell proliferation.

[4]  Lei Sun,et al.  MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression , 2015, PloS one.

[5]  Massimo Negrini,et al.  Absolute quantification of cell-free microRNAs in cancer patients , 2015, Oncotarget.

[6]  Kunio Matsumoto,et al.  Hepatocyte growth factor and Met in drug discovery. , 2015, Journal of biochemistry.

[7]  Ja Hyun Koo,et al.  Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction , 2015, Oncotarget.

[8]  Q. Kan,et al.  MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET , 2015, Tumor Biology.

[9]  Fangzhou Song,et al.  MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met , 2015, Tumor Biology.

[10]  E. Lengyel,et al.  The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma , 2015, Oncotarget.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  Xiaoyang Xu,et al.  Cancer Nanomedicine: From Targeted Delivery to Combination Therapy , 2015, Trends in molecular medicine.

[13]  S. Pfeffer,et al.  miR-122--a key factor and therapeutic target in liver disease. , 2015, Journal of hepatology.

[14]  Jinhua Wang,et al.  MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A , 2014, Oncotarget.

[15]  M. Copin,et al.  Thirty years of research on met receptor to move a biomarker from bench to bedside. , 2014, Cancer research.

[16]  P. Fu,et al.  MicroRNA-185 inhibits proliferation by targeting c-Met in human breast cancer cells , 2014, Experimental and therapeutic medicine.

[17]  Xing Chen,et al.  MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. , 2014, Cancer letters.

[18]  A. Can,et al.  Reciprocal Activating Crosstalk between c-Met and Caveolin 1 Promotes Invasive Phenotype in Hepatocellular Carcinoma , 2014, PloS one.

[19]  E. Erdal,et al.  MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. , 2014, Biochemical and biophysical research communications.

[20]  F Levi,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  K. Garber.  MET inhibitors start on road to recovery , 2014, Nature Reviews Drug Discovery.

[22]  S. Zhuang,et al.  MicroRNA-148a suppresses the epithelial–mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling , 2014, Oncogene.

[23]  D. Brown,et al.  Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer , 2014, Molecular Cancer Therapeutics.

[24]  Zhonghan Li,et al.  Therapeutic targeting of microRNAs: current status and future challenges , 2014, Nature Reviews Drug Discovery.

[25]  F. Rojo,et al.  High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients , 2014, Oncotarget.

[26]  C. Maroun,et al.  The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. , 2014, Pharmacology & therapeutics.

[27]  H. Hermeking,et al.  The p53/miR-34 axis in development and disease. , 2014, Journal of molecular cell biology.

[28]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[29]  Yang Peng,et al.  MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression , 2014, Bioscience reports.

[30]  Q. Ye,et al.  MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway , 2014, Hepatology.

[31]  Jingnan Wang,et al.  Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET , 2014, Clinical Cancer Research.

[32]  H. Hermeking,et al.  miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. , 2014, Cell reports.

[33]  L. Schwartz,et al.  Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. , 2014, Hepatic oncology.

[34]  Jiwei Huang,et al.  miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma , 2014, Tumor Biology.

[35]  R. Knight,et al.  miR-34: from bench to bedside , 2014, Oncotarget.

[36]  Lihua Li,et al.  MiR-133b Is Down-Regulated in Human Osteosarcoma and Inhibits Osteosarcoma Cells Proliferation, Migration and Invasion, and Promotes Apoptosis , 2013, PloS one.

[37]  H. Qin,et al.  MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. , 2013, Biochemical and biophysical research communications.

[38]  Rounak Nassirpour,et al.  miR-122 Regulates Tumorigenesis in Hepatocellular Carcinoma by Targeting AKT3 , 2013, PloS one.

[39]  Zhao-You Tang,et al.  MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA through the PIK3C2α/Akt/HIF-1α Pathway in Hepatocellular Carcinoma , 2013, PloS one.

[40]  T. Utsugi.  New Challenges and Inspired Answers for Anticancer Drug Discovery and Development , 2013, Japanese journal of clinical oncology.

[41]  T. Shibata,et al.  miR‐148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells , 2013, Hepatology.

[42]  A. He,et al.  Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations , 2013, Therapeutic advances in gastroenterology.

[43]  G. V. Vande Woude,et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.

[44]  H. Cai,et al.  miR-26a and its Target CKS2 Modulate Cell Growth and Tumorigenesis of Papillary Thyroid Carcinoma , 2013, PloS one.

[45]  E. Wang,et al.  MicroRNA-449a Is Downregulated in Non-Small Cell Lung Cancer and Inhibits Migration and Invasion by Targeting c-Met , 2013, PloS one.

[46]  Y. Dang,et al.  Underexpression of miR-34a in Hepatocellular Carcinoma and Its Contribution towards Enhancement of Proliferating Inhibitory Effects of Agents Targeting c-MET , 2013, PloS one.

[47]  S. Giordano,et al.  MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? , 2013, Hepatology.

[48]  H. Hermeking,et al.  Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer , 2012, Clinical Cancer Research.

[49]  C. Korch,et al.  Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis , 2012, Molecular Cancer.

[50]  Brigitte Schlegelberger,et al.  Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. , 2012, Gastroenterology.

[51]  H. Tanzawa,et al.  Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. , 2012, Anticancer research.

[52]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[53]  Andrew L. Kung,et al.  Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia , 2012, Nature Medicine.

[54]  S. Peters,et al.  MET: a promising anticancer therapeutic target , 2012, Nature Reviews Clinical Oncology.

[55]  H. Hosoda,et al.  Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. , 2012, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[56]  M. Gariboldi,et al.  miRNA Profiling in Colorectal Cancer Highlights miR-1 Involvement in MET-Dependent Proliferation , 2012, Molecular Cancer Research.

[57]  C. Croce,et al.  miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 , 2012, Oncogene.

[58]  C. Rountree,et al.  c‐Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma , 2011, Hepatology.

[59]  Rui Li,et al.  miR‐198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c‐MET pathway , 2011, FEBS letters.

[60]  Xiao-nan Wang,et al.  miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met , 2011, Cancer.

[61]  H. Mankin,et al.  MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration , 2011, Molecular Cancer Therapeutics.

[62]  Ashley P E Roberts,et al.  miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components , 2011, Nucleic acids research.

[63]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[64]  Toshikazu Nakamura,et al.  Hepatocyte growth factor twenty years on: Much more than a growth factor , 2011, Journal of gastroenterology and hepatology.

[65]  Thomas D. Schmittgen,et al.  miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. , 2010, Biochemical and biophysical research communications.

[66]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[67]  Shi‐Mei Zhuang,et al.  A novel GSK‐3 beta–C/EBP alpha–miR‐122–insulin‐like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma , 2010, Hepatology.

[68]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[69]  T. Ohira,et al.  Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma , 2010, Clinical Cancer Research.

[70]  A. Levitzki,et al.  Signal transduction therapy of cancer. , 2010, Molecular aspects of medicine.

[71]  Xiaorong Li,et al.  miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[72]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[73]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[74]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[75]  S. Thorgeirsson,et al.  Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.

[76]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[77]  C. Croce,et al.  MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. , 2009, Cancer research.

[78]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[79]  Hsien-Da Huang,et al.  MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma , 2009, Hepatology.

[80]  G. V. Vande Woude,et al.  Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer , 2009, Clinical Cancer Research.

[81]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[82]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[83]  C. Jopling.  Regulation of hepatitis C virus by microRNA-122. , 2008, Biochemical Society transactions.

[84]  Laura Pelletier,et al.  MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations , 2008, Hepatology.

[85]  P. Schirmacher,et al.  MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma , 2007, Hepatology.

[86]  F. Wong-Staal,et al.  Development of new RNAi therapeutics. , 2007, Histology and histopathology.

[87]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[88]  Toshikazu Nakamura,et al.  Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.

[89]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[90]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[91]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[92]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[93]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[94]  M. Fukuoka,et al.  Molecular target-based cancer therapy: tyrosine kinase inhibitors , 2003, International Journal of Clinical Oncology.

[95]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[96]  Patricia Dilouie.  Try and try again , 1997 .

[97]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[98]  Leaf Huang,et al.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.

[99]  Gene expression and miRNAs profiling RNA samples were processed for mRNA microarray hybridization by the INT-MI Functional Genomics , 2014 .

[100]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[101]  J. Llovet,et al.  Medical therapies for hepatocellular carcinoma: a critical view of the evidence , 2013, Nature Reviews Gastroenterology &Hepatology.

[102]  C. Esau,et al.  Inhibition of microRNA with antisense oligonucleotides. , 2008, Methods.

[103]  S. Schnitt,et al.  Expression of scatter factor and c-met receptor in benign and malignant breast tissue. , 1997, Cancer.

[104]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.